Recursion Reports Third Quarter 2026 Financial Results and Extends Cash Runway; Highlights Positive Clinical Data in REC-4881 and REC-1245, Sanofi Development Candidate Option and Appointment of Fred Hassan as Chair
Sanofi’s option adds a $10 million milestone payment, while Recursion guides to cash operating expenses below $360 million in 2027.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Recursion (RXRX) reported third-quarter 2026 results, updated clinical trial data and extended its expected cash runway into 2029. The runway includes October offering proceeds. Cash operating expense guidance remains below $375 million for 2026, with below $360 million guided for 2027.
After 12 weeks of REC-4881 treatment, 13 of 15 patients had reduced total polyp burden, with a 47% median reduction. Twelve weeks off treatment, 11 of 13 evaluable patients remained below baseline. REC-1245 produced two confirmed and one unconfirmed partial responses at doses of at least 45 mg, with 91.7% disease control in 12 patients.
Sanofi optioned a development candidate, triggering a $10 million milestone; Sanofi will fund and lead further development. Genentech exercised its first neuroscience Validated Target Option. Fred Hassan became Board Chair effective October 31, 2026.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate point. Forward-looking: it has not happened yet and may not happen.Expected cash runway extends into 2029, including October 2026 follow-on offering proceeds.
- Moderate point. Forward-looking: it has not happened yet and may not happen.Cash operating expense guidance is below $375 million for 2026 and below $360 million for 2027.
- Moderate pointREC-4881 reduced total polyp burden in 87% (13 of 15) after 12 weeks; median reduction was 47%.
- Moderate point. Forward-looking: it has not happened yet and may not happen.Recursion plans to focus resources on five internal programs and partnerships, and seek partners for REC-617 and REC-3565.
- Moderate point. Forward-looking: it has not happened yet and may not happen.Sanofi will fund and lead further development and commercialization; Phase 1 is expected to begin in 2027.
- Moderate pointGenentech exercised its first Validated Target Option, advancing a neuroscience target into early discovery.
22 minor points
- Minor pointREC-4881 total polyp burden remained below baseline in 85% (11 of 13) evaluable patients 12 weeks off treatment.
- Minor pointREC-4881 upper GI burden fell in 92% (12 of 13) after 12 weeks; median reduction was 55%.
- Minor pointREC-4881 upper GI reductions reached at least 98% in two patients after 12 weeks.
- Minor pointREC-4881 improved upper GI disease classification by at least one Spigelman stage in 6 of 12 patients.
- Minor pointREC-4881 upper GI burden remained below baseline in 92% (11 of 12) 12 weeks off treatment.
- Minor pointREC-4881 lower GI burden fell in 82% (9 of 11); median reduction was 50% after 12 weeks.
- Minor pointREC-4881 lower GI burden remained below baseline in 70% of evaluable patients 12 weeks off treatment.
- Minor pointREC-4881 reduced counts of polyps larger than 5 mm in 6 of 8 patients after 12 weeks.
- Minor pointLarger-polyp counts fell at least 80% in four patients, including two declining from more than 90 to one.
- Minor pointLarger-polyp counts remained below baseline in 6 of 8 patients 12 weeks after stopping REC-4881.
- Minor pointREC-4881 showed no new safety signals, no Grade 4/5 treatment-related adverse events and no additional discontinuations.
- Minor pointREC-1245 produced two confirmed endometrial cancer responses and one unconfirmed liver cancer response at doses ≥45 mg.
- Minor pointREC-1245 disease control reached 91.7% (11/12) at doses ≥45 mg.
- Minor pointREC-1245 at 45 mg daily (n=10) showed no dose-limiting toxicities or treatment-related serious adverse events.
- Minor point. Forward-looking: it has not happened yet and may not happen.REC-1245 45 mg daily was selected for exploratory expansion; preliminary endometrial cancer data are expected in second-half 2027.
- Minor pointREC-7735 entered the Phase 1/2 ZINNIA study in the second half of 2026.
- Minor pointSanofi’s candidate option triggered $10 million, bringing collaboration upfront and milestone payments achieved to $144 million.
- Minor point. Forward-looking: it has not happened yet and may not happen.Sanofi program eligibility includes more than $300 million in additional milestones and double-digit royalties on sales, if approved.
- Minor point. Forward-looking: it has not happened yet and may not happen.Sanofi collaboration programs could reach development-candidate and other progress-based milestones over the next 12 months.
- Minor pointRoche/Genentech collaboration upfront and milestone payments achieved total $216 million.
- Minor point. Forward-looking: it has not happened yet and may not happen.Roche/Genentech collaboration covers up to 40 potential programs, each potentially carrying more than $300 million in milestones.
- Minor point. Forward-looking: it has not happened yet and may not happen.Roche/Genentech small-molecule programs carry potential tiered royalties up to high single digits.
Negative
- Minor pointREC-4881 caused Grade 3 treatment-related adverse events in four patients (15%).
- Minor point. Forward-looking: it has not happened yet and may not happen.REC-4881 registrational trial initiation is anticipated in second-half 2027, pending ongoing FDA discussions.
- Minor pointREC-1245 treatment-related fatigue and anemia each affected 30% at 45 mg daily, all Grade 1 or 2.
News Explained
The Sanofi option milestone brings total upfront and milestone payments under the collaboration to
Key Figures
- Median polyp-burden reduction
- 47%
- REC-4881 Phase 2; after 12 weeks in the expanded adult FAP population
- Below-baseline polyp burden
- 85% (11 of 13 patients)
- REC-4881; 12 weeks after stopping treatment
- Disease control rate
- 91.7% (11 of 12 patients)
- REC-1245 at doses of at least 45 mg
- Sanofi milestone payment
- $10 million
- Triggered by Sanofi's development-candidate option
- Potential additional milestones
- More than $300 million
- Potential future milestones under the Sanofi program
- Cash runway
- Into 2029
- Based on current operating plans with no additional financing
- Cash operating expense guidance
- Less than $375 million
- 2026 guidance, reiterated
- Cash operating expense guidance
- Less than $360 million
- 2027 guidance
Historical Context
-
Reported 47% median polyp-burden reduction; 85% remained below baseline after 12 weeks off treatment.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
mek1/2 inhibitor medical
disease control rate medical
dose-limiting toxicities medical
recist 1.1 medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
- New Phase 2 REC-4881 data presented at CGA-IGC in an expanded adult population aged 18 years and older show deep, durable polyp burden reductions in FAP, with activity throughout the GI tract and in larger, higher-risk polyps.
- REC-4881 shows deep activity throughout the GI tract in post colectomy patients, including near-clearance: After 12 weeks of treatment, nearly 1 in 2 patients in the upper GI and more than 1 in 3 in the lower GI achieved polyp burden reductions of ≥
65% . Two patients achieved ≥98% reductions in upper GI polyp burden. - REC-4881 reductions persisted off treatment: Twelve weeks after stopping treatment,
85% of evaluable patients remained below baseline polyp burden. - REC-4881 reductions in larger, higher-risk polyps: Six of eight patients with polyps >5 mm at baseline had reductions in these polyp counts after 12 weeks of treatment; four had reductions of at least
80% , including two whose larger-polyp counts fell from more than 90 to one. - REC-4881 no new safety signals observed: Favorable chronic dosing safety profile, with predominantly Grade 1/2 AEs, and no additional discontinuations reported since the prior data cutoff.
- REC-1245 Phase 1 data update: Encouraging monotherapy activity with 2 confirmed partial responses in endometrial cancer, 1 unconfirmed partial response in liver cancer, and a
91.7% disease control rate (11/12) at doses ≥45 mg; 45 mg selected for exploratory expansion cohorts based on emerging efficacy and manageable safety profile. - Sanofi options the first development candidate from Recursion collaboration, a potential first-in-class, dual targeting inhibitor oral small molecule in immunology, which will now advance into Sanofi’s portfolio, with Phase 1 clinical study expected to begin in 2027.
- Expected cash runway extended into 2029, including proceeds from the October 2026 follow-on offering; 2026 cash operating expense guidance reiterated at less than
$375 million , with 2027 guidance of less than$360 million . - Appointed Fred Hassan as Chair of the Board, effective October 31, 2026. Mr. Hassan brings more than four decades of pharmaceutical leadership and Board experience across company transformation, drug development and commercialization.
SALT LAKE CITY, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical-stage company pioneering AI-enabled drug discovery and development, today reported financial results for the third quarter ended September 30, 2026, together with business updates highlighting continued clinical, pipeline and platform execution.
Recursion will host a webinar with earnings updates on REC-4881 data, REC-1245 data, as well as REC-4881 KOL and patient panels, presented live from CGA-IGC on Tuesday, November 3, 2026 at 8:00 am ET / 6:00 am MT / 1:00 pm GMT from Recursion’s X, LinkedIn, and YouTube accounts giving analysts, investors, and the public the opportunity to ask questions of the Company by submitting questions here: Question Form.
“To pioneer a new blueprint for making medicines with AI, we believe you have to tie together three core capabilities in one engine: uncover novel biology, design differentiated molecules against challenging targets, and generate clinical evidence that matters for patients,” said Najat Khan, Ph.D., President and Chief Executive Officer of Recursion. “The new TUPELO data are important clinical evidence, with REC-4881 showing deep polyp burden reductions across the upper and lower GI tract, including larger, higher-risk polyps, and reductions that persist after treatment stops. REC-1245 is an encouraging early example of that engine coming together within a single program, from biological insight surfaced by our platform to molecule design and now early clinical signals in heavily pretreated patients.”
“Beyond our own pipeline, Sanofi has optioned a potential first-in-class molecule against a challenging dual target, while Genentech has advanced an unexplored neuroscience target from our maps. These are different programs, but they are outputs of the same AI-native engine, providing evidence of repeatability. We will keep concentrating capital where the evidence is strongest and turning innovation into impact for patients who are waiting.”
Internal Pipeline Highlights
Recursion internal pipeline: five oncology and rare-disease programs (REC-4881, REC-1245, REC-4539, REC-7735, REC-102) shown by target, indication, addressable patient population, development stage, next catalyst, and AI-enabled differentiation.
Positive Phase 2 results from ongoing TUPELO trial of REC-4881 in FAP highlight activity across GI tract and on larger polyps
FAP is a genetically defined driver of GI cancer, affecting >50,000 patients in the US and EU5 who face major surgeries and life-long surveillance with no approved therapies, representing a potential
REC-4881, a potential first-in-class oral therapy granted FDA Orphan Drug and Fast Track designations, is designed to address both Wnt/β-catenin initiation and MAPK evolution pathways. The opportunity was identified through unbiased phenotypic screening using Recursion’s proprietary AI foundation models, which revealed MEK1/2 inhibition as a potential way to reverse cellular phenotypes associated with APC loss, a previously unappreciated synthetic rescue relationship.
On November 2, Recursion announced further positive data from its ongoing Phase 1b/2 TUPELO trial of REC-4881, an investigational, oral MEK1/2 inhibitor in development for FAP. These data were presented by Lisa Boardman, M.D., Professor of Medicine at Mayo Clinic, in a presidential plenary session at The Collaborative Group of the Americas on Inherited Gastrointestinal Cancer (CGA-IGC) Annual Meeting in Denver, Colorado.
- Deep, durable reductions in total polyp burden, strengthened in the expanded adult FAP population (18+): After 12 weeks of REC-4881 (4 mg QD),
87% of patients (13 of 15) had a reduction in total polyp burden, with a47% median reduction; approximately 1 in 3 achieved reductions of ≥65% . Twelve weeks after stopping treatment,85% of evaluable patients (11 of 13) remained below baseline. - Activity across the upper and lower GI tract, including near-clearance: After 12 weeks of treatment, median polyp burden reductions were
55% in the upper GI and50% in the lower GI, supporting REC-4881’s potential as a single oral therapy to address FAP across the GI tract. - Upper GI, the area of greatest unmet need in FAP (results first reported Oct. 15):
92% of patients (12 of 13) had reductions after 12 weeks of treatment, with two patients achieving ≥98% reductions; half (6 of 12) improved by at least one Spigelman stage; and92% (11 of 12) remained below baseline 12 weeks after stopping treatment. - New lower GI results highlight breadth of activity: 9 of 11 patients (
82% ) with measurable lower GI polyp burden at baseline had reductions after 12 weeks of treatment, with a50% median reduction and 1 in 3 achieving ≥65% ;70% of evaluable patients remained below baseline 12 weeks after stopping treatment. - New analysis shows substantial reductions in larger, higher-risk polyps: 6 of 8 patients with polyps >5 mm at baseline had fewer of these polyps after 12 weeks of treatment. Four achieved reductions of ≥
80% , including two whose counts fell from more than 90 polyps to one. Six of eight remained below their baseline count 12 weeks after stopping treatment. - No new safety signals observed: Favorable chronic dosing safety profile. The highest-grade treatment-related adverse event was Grade 1 or 2 in 21 of 26 patients (
81% ) and Grade 3 in four patients (15% ); one patient had no TRAEs. No Grade 4 or 5 TRAEs, and no additional discontinuations since the previous data cutoff.
The Company anticipates initiating a registrational trial in the second half of 2027, pending ongoing FDA discussions, and will provide additional details later this year.
Early data from the Phase 1 dose-escalation portion of DAHLIA, our ongoing open-label Phase 1/2 study of REC-1245, show the following (data cutoff: August 21, 2026):
REC-1245 is a potential first-in-class oral molecular glue designed to exploit a synthetic-lethal vulnerability in cancers by degrading RBM39, a splicing factor that regulates genes involved in DNA repair and stress response. The Recursion platform contributed each of the three core elements of the program: the target, the molecule and the initial hypotheses on which patients are most likely to benefit. The target emerged from Recursion’s platform, which found that degrading RBM39 mimics the loss of CDK12, while sparing CDK13-associated liabilities. REC-1245 was identified within 18 months after screening only 204 compounds using Recursion’s design platform. The same platform-derived biology pointed to tumors intrinsically primed by replication stress and reliance on accurate splicing, including hard-to-treat cancers such as endometrial, hepatocellular and ovarian cancers and transcriptionally driven tumors.
- Three partial responses per RECIST 1.1 criteria (2 confirmed, 1 unconfirmed) in heavily pretreated patients with endometrial cancer and hepatocellular carcinoma, all at doses of 45 mg once daily (QD) or higher, with a disease control rate of
91.7% at those doses (n=12). - Recursion has selected 45 mg QD for exploratory expansion cohorts, including endometrial cancer, where limited second-line treatments are approved; at the 45 mg QD dose (n=10), no dose-limiting toxicities or treatment-related serious adverse events were observed, and treatment-related adverse events were predominantly Grade 1 or 2. Most frequent TRAEs were Grade 1 or Grade 2 fatigue and anemia (
30% each). - Preliminary dose expansion data in endometrial cancer are expected in the second half of 2027. Dose escalation will also continue in other solid tumor indications.
Other Portfolio Updates: REC-7735 is an orally bioavailable, precision-designed small molecule inhibitor of PI3Kα H1047R generated using the Recursion OS. In the second half of 2026, Recursion initiated the Phase 1/2 ZINNIA clinical study for patients with select PIK3CA H1047R-mutant solid tumors.
As announced in October 2026, given the promising data in REC-4881 and REC-1245, Recursion plans to continue to focus resources on its high-impact partnerships and internal programs including REC-4881 (MEK1/2 - familial adenomatous polyposis), REC-1245 (RBM39 - endometrial cancer and other solid tumors), REC-4539 (LSD1 - solid tumors and hematology), REC-7735 (PI3Kα H1047R - solid tumors) and REC-102 (ENPP1 - hypophosphatasia). Recursion intends to pursue partnership opportunities to advance REC-617 (CDK7) and REC-3565 (MALT1).
Partnered Discovery Highlights Recursion’s 9th Milestone Achieved in Past Two Years
Sanofi options potential first-in-class immunology development candidate
Sanofi has optioned the first development candidate from the two companies’ multi-program research collaboration. The candidate has now been added to Sanofi’s development pipeline and is expected to enter Phase 1 clinical trials in 2027, with Sanofi funding and leading further development and commercialization to advance the program toward patients.
The option triggered a
The potential first-in-class oral small molecule was designed to achieve a differentiated profile against a challenging dual target implicated in inflammatory disease. Optimizing for this target pair required navigating complex and competing chemistry constraints to achieve the desired balance of drug-like properties. The candidate was delivered by the combination of Recursion’s integrated AI-enabled drug design platform and small-molecule chemistry capabilities with Sanofi’s deep expertise in drug discovery and immunology. Recursion applied multiple computational design approaches across iterative cycles of prediction, chemical design, synthesis, and experimental validation to rapidly explore and optimize a complex chemical space.
With the first development candidate optioned, the collaboration has now achieved six progress-based milestones across five programs. Additional programs across the collaboration continue to advance. Over the next 12 months, other programs in the joint portfolio have the potential to reach development candidate and other progress-based milestones.
To learn more about this milestone, read the press release.
Genentech advanced first neuroscience target into early discovery program
In 3Q26, Genentech exercised the first Validated Target Option under the companies' neuroscience collaboration, advancing a previously unexplored neuroscience target.
The milestone provides additional early evidence that Recursion's AI-native platform can both discover and play a key role experimentally validating unexplored therapeutic targets in neuroscience, one of medicine's most challenging therapeutic areas, where decades of research have largely focused on a limited number of well-studied targets. Predictions generated from the first whole-genome CRISPR knockout map, which was built by Recursion in partnership with Roche and Genentech from a subset of over 1 trillion internally manufactured iPSC-derived neuronal cells, were rigorously jointly validated with Genentech. Only targets that consistently demonstrated compelling evidence across pathway, functional, and disease validation progress into a validation package.
Next steps will include advancing the target through small molecule design, hit generation, and validation using Recursion's AI-native chemistry platform. More broadly, the neuronal and microglial maps of biology remain reusable assets capable of being collaboratively utilized with biological, genetics, and computational expertise to generate and experimentally validate additional therapeutic hypotheses. To date, Recursion has achieved
Potential upcoming milestones across partnered discovery:
- Potential for additional differentiated AI-enabled oral molecules to reach development candidate and late-stage discovery milestones with Sanofi over the next 12 months
- Translating AI-driven insights from maps of biology into new potentially novel targets from reusable high-dimensional data/maps with Roche and Genentech
- Using Recursion’s chemistry platform to design potential first-in-class molecules for the collaboration's first neuroscience target with Genentech
Fred Hassan appointed Chair of the Board
Recursion announced that its Board of Directors has appointed Fred Hassan as Chair, effective October 31, 2026.
Mr. Hassan brings more than four decades of pharmaceutical leadership spanning company transformation, drug development, commercialization, investing and Board service. As Chairman and Chief Executive Officer of Schering-Plough, he led a transformation that restored sales growth and strong cash flow while expanding the company’s Phase 3 pipeline from three new molecular entities to eight. He previously served as Chairman and Chief Executive Officer of Pharmacia.
Mr. Hassan also brings extensive perspective from across the biotechnology and investment ecosystem. He serves as Lead Independent Director of BridgeBio Pharma, where his Board tenure has spanned the FDA approval and U.S. launch of Attruby, and as Executive Chair of Norstella, the pharmaceutical intelligence company behind Citeline, MMIT and Evaluate. His prior Board roles include Amgen and Prometheus Biosciences. He is also a Director at Warburg Pincus, where he previously served as Partner and Managing Director.
Third Quarter 2026 Financial Results
- Cash Position: Cash, cash equivalents and restricted cash were
$561.5 million as of September 30, 2026. Including net proceeds of approximately$187.2 million from the Company's underwritten offering which completed on October 16, 2026, pro forma cash, cash equivalents and restricted cash were approximately$748.7 million . Based on current operating plans with no additional financing, the Company expects its cash runway to extend into 2029. - Revenue: Total revenue, consisting primarily of revenue from collaboration agreements, was
$18.6 million for the third quarter of 2026, compared to$5.2 million for the third quarter of 2025. The increase was driven primarily by the Company’s collaboration with Sanofi, under which the Company achieved a$10.0 million milestone for an immunology small molecule program during the quarter. - Research and Development Expenses: Research and development expenses were
$99.1 million for the third quarter of 2026, compared to$121.1 million for the third quarter of 2025. The decrease was driven primarily by$22.8 million of in-process research and development costs related to the acquisition of full rights to REC-102, Recursion’s ENPP1 inhibitor for the treatment of hypophosphatasia (HPP), from its joint venture with Rallybio that were recognized in the third quarter of 2025 and did not recur in the current period. - General and Administrative Expenses: General and administrative expenses were
$32.6 million for the third quarter of 2026 compared to$41.6 million for the third quarter of 2025. The decrease in general and administrative expense compared to the prior period was primarily driven by a decrease in infrastructure technology expenses and professional service costs. - Net Loss: Net loss was
$119.0 million for the third quarter of 2026, compared to a net loss of$162.3 million for the third quarter of 2025. - Operational Cash Flows: Net cash used in operating activities was
$77.4 million for the three months ended September 30, 2026, compared to net cash used in operating activities of$117.4 million for the three months ended September 30, 2025. The decrease in cash used in operating activities was primarily driven by operating efficiencies across the company and working capital movements. - Cash Operating Expense: Cash operating expense, excluding partnership inflows and transaction costs, for the nine months ended September 30, 2026 was
$271.5 million compared to$323.1 million for the nine months ended September 30, 2025.
About Recursion
Recursion (NASDAQ: RXRX) is a leading clinical-stage company pioneering AI-enabled drug discovery and development decoding biology to radically improve lives. Recursion is advancing a portfolio of differentiated investigational medicines across its wholly owned and partnered pipeline in oncology, rare disease, neuroscience, immunology, and other therapeutic areas with significant unmet need. Enabling its mission is the Recursion OS, an AI-native, end-to-end drug discovery and development platform integrating biology, chemistry, and clinical development into a unified intelligence system. Powered by proprietary multimodal data, purpose-built AI models, and bilingual teams fluent in both science and AI, the Recursion OS is designed to translate complex science into medicines that matter — faster, better, and at scale — for patients who are waiting.
Recursion's platform infrastructure is anchored in Salt Lake City, Utah and Milton Park, Oxfordshire, where its automated biology and chemistry laboratories generate proprietary data at industrial scale. Recursion also maintains offices in New York, Montréal, and London, three global hubs for talent and leadership at the intersection of AI and scientific innovation.
Media Contact
media@recursion.com
Investor Contact
investor@recursion.com
| Recursion Pharmaceuticals Inc Condensed Consolidated Statements of Operations (unaudited) |
| (in thousands, except share and per share amounts) |
| Three months ended September 30, | Nine months ended September 30, | ||||||||||||
| 2026 | 2025 | 2026 | 2025 | ||||||||||
| Revenue | |||||||||||||
| Operating revenue | $ | 18,055 | $ | 4,983 | $ | 31,659 | $ | 38,905 | |||||
| Grant revenue | 497 | 192 | 1,035 | 238 | |||||||||
| Total revenue | 18,552 | 5,175 | 32,694 | 39,143 | |||||||||
| Operating costs and expenses | |||||||||||||
| Cost of revenue | 10,045 | 14,687 | 34,026 | 56,678 | |||||||||
| Research and development | 99,122 | 121,062 | 276,632 | 379,331 | |||||||||
| General and administrative | 32,561 | 41,628 | 108,684 | 142,932 | |||||||||
| Total operating costs and expenses | 141,728 | 177,377 | 419,342 | 578,941 | |||||||||
| Loss from operations | (123,176 | ) | (172,202 | ) | (386,648 | ) | (539,798 | ) | |||||
| Other income, net | 4,165 | 9,952 | 14,524 | 3,005 | |||||||||
| Loss before income taxes | (119,011 | ) | (162,250 | ) | (372,124 | ) | (536,793 | ) | |||||
| Income tax benefit (expense) | (25 | ) | (3 | ) | 4,579 | 156 | |||||||
| Net loss | $ | (119,036 | ) | $ | (162,253 | ) | $ | (367,545 | ) | $ | (536,637 | ) | |
| Per share data | |||||||||||||
| Net loss per share of Class A, B and Exchangeable common stock, basic and diluted | $ | (0.22 | ) | $ | (0.36 | ) | $ | (0.69 | ) | $ | (1.27 | ) | |
| Weighted-average shares (Class A, B and Exchangeable) outstanding, basic and diluted | 543,000,977 | 446,988,046 | 534,971,854 | 422,642,653 | |||||||||
Recursion Pharmaceuticals Inc
Condensed Consolidated Balance Sheets (unaudited)
(in thousands)
| September 30, | December 31, | |||||
| 2026 | 2025 | |||||
| Assets | ||||||
| Current assets | ||||||
| Cash and cash equivalents | $ | 549,853 | $ | 743,294 | ||
| Restricted cash | 6,657 | 4,594 | ||||
| Other receivables | 34,065 | 24,649 | ||||
| Prepaid data assets | 2,882 | 11,742 | ||||
| Other current assets | 22,564 | 28,566 | ||||
| Total current assets | 616,021 | 812,845 | ||||
| Restricted cash, non-current | 5,020 | 6,033 | ||||
| Property and equipment, net | 85,838 | 103,931 | ||||
| Operating lease right-of-use assets | 51,198 | 45,339 | ||||
| Financing lease right-of-use assets | 15,663 | 20,210 | ||||
| Intangible assets, net | 273,677 | 309,903 | ||||
| Goodwill | 160,710 | 162,158 | ||||
| Deferred tax assets | 957 | 957 | ||||
| Other assets, non-current | 12,628 | 12,754 | ||||
| Total assets | $ | 1,221,712 | $ | 1,474,130 | ||
| Liabilities and stockholders’ equity | ||||||
| Current liabilities | ||||||
| Accounts payable | $ | 16,384 | $ | 18,118 | ||
| Accrued expenses and other liabilities | 66,651 | 70,230 | ||||
| Unearned revenue | 15,811 | 37,605 | ||||
| Operating lease liabilities | 12,264 | 12,663 | ||||
| Notes payable and financing lease liabilities | 11,808 | 9,091 | ||||
| Total current liabilities | 122,918 | 147,707 | ||||
| Unearned revenue, non-current | 120,020 | 114,012 | ||||
| Operating lease liabilities, non-current | 50,535 | 46,647 | ||||
| Notes payable and financing lease liabilities, non-current | 93 | 9,564 | ||||
| Deferred tax liabilities | 18,371 | 23,255 | ||||
| Other liabilities, non-current | 3,963 | 2,080 | ||||
| Total liabilities | 315,900 | 343,265 | ||||
| Stockholders’ equity | ||||||
| Common stock | 6 | 5 | ||||
| Additional paid-in capital | 3,319,723 | 3,170,145 | ||||
| Accumulated deficit | (2,443,547 | ) | (2,076,002 | ) | ||
| Accumulated other comprehensive income | 29,630 | 36,717 | ||||
| Total stockholders’ equity | 905,812 | 1,130,865 | ||||
| Total liabilities and stockholders’ equity | $ | 1,221,712 | $ | 1,474,130 | ||
Recursion Pharmaceuticals Inc
Selected Cash Flow Information (unaudited)
(in thousands)
| Three months ended September 30, | Nine months ended September 30, | ||||||||||||
| 2026 | 2025 | 2026 | 2025 | ||||||||||
| Net cash used in operating activities | $ | (77,406 | ) | $ | (117,360 | ) | $ | (264,454 | ) | $ | (325,735 | ) | |
| Net cash used in investing activities | (407 | ) | (2,549 | ) | (2,704 | ) | (15,627 | ) | |||||
| Net cash provided by (used in) financing activities | 83,144 | 251,340 | 78,407 | 389,526 | |||||||||
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | (621 | ) | 1,869 | (3,640 | ) | 15,957 | |||||||
| Cash, cash equivalents and restricted cash, beginning of period | 556,820 | 533,845 | 753,921 | 603,024 | |||||||||
| Cash, cash equivalents and restricted cash, end of period | $ | 561,530 | $ | 667,145 | |||||||||
Non-GAAP Financial Measure
The reconciliation of operating cash expense to net cash used in operating activities is provided in the following tables:
| Cash Operating Expense - Nine months ended September 30, 2026 | (in millions) | ||
| Net cash used in operating activities | $ | 264.5 | * |
| Add: partnership inflows | 7.0 | ||
| Cash Operating Expense - Nine months ended September 30, 2026 | $ | 271.5 | |
*This is from the Recursion Inc Consolidated Statement of Cash Flows for the nine months ended September 30, 2026 (see above)
| Cash Operating Expense - Nine months ended September 30, 2025 | (in millions) | |||
| Net cash used in operating activities | $ | 325.7 | * | |
| Add: partnership inflows | 7.0 | |||
| Subtract: Transaction costs | (9.6 | ) | ||
| Cash Operating Expense - Nine months ended September 30, 2025 | $ | 323.1 | ||
*This is from the Recursion Inc Consolidated Statement of Cash Flows for the nine months ended September 30, 2025 (see above)
To supplement our financial statements prepared in accordance with U.S. GAAP, we monitor and consider operating cash expense, which is a non-GAAP financial measure. We define cash operating expense as the net cash used in operating activities, excluding non-ordinary course transaction costs and partnership cash inflows. This non-GAAP financial measure is not based on any standardized methodology prescribed by U.S. GAAP and is not necessarily comparable to similarly-titled measures presented by other companies. We believe operating cash expense to be a liquidity measure that provides useful information to management and investors about the amount of cash consumed by the operations of the business. A limitation of using this non-U.S. GAAP measure is that operating cash expense does not represent the total change in cash and cash equivalents for the period because it excludes cash provided by or used for other investing and financing activities. We account for this limitation by providing information about our capital expenditures and other investing and financing activities in the statements of cash flows in our financial statements. Additionally, we reconciled operating cash expense above to net cash used in operating activities, the most directly comparable U.S. GAAP financial measure. In addition, it is important to note that other companies, including companies in our industry, may not use operating cash expense, may calculate operating cash expense in a different manner than we do or may use other financial measures to evaluate their performance, all of which could reduce the usefulness of operating cash expense as a comparative measure. Because of these limitations, operating cash expense should not be considered in isolation from, or as a substitute for, financial information prepared in accordance with U.S. GAAP.
Forward-Looking Statements
This document contains information that includes or is based upon “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, those regarding the impact of preclinical and clinical data from our programs, including the Phase 2 data from the TUPELO trial of REC-4881; the timing and outcome of anticipated engagement with the FDA, including the definition of a registrational path for REC-4881; the impact of the Phase 1 data from the DAHLIA trial of REC-1245 on the future success of that program; the selection of a dose for REC-1245 expansion cohorts; the potential for REC-7735 to limit metabolic liabilities and improve therapeutic index; Recursion’s ability to translate platform insights into validated targets and optimized development candidates; Recursion’s plans to focus resources on its high-impact partnerships and internal programs and to pursue partnership opportunities for REC-617 and REC-3565; the expected initiation of a Phase 1 clinical study of the development candidate optioned by Sanofi; the impact of Genentech’s option of any neuroscience target on future development of that or other potential targets; the reusability of our maps of biology and the potential to generate and experimentally validate additional therapeutic hypotheses, including through multi-modal maps combining our phenomics data with partner-provided data; financial position, including the expected impact of the net proceeds of our October 2026 underwritten offering, cash runway, cash burn, and 2026 and 2027 cash operating expense guidance; the occurrence or realization of potential milestones; the timing of data readouts and other milestones; Recursion’s future as a leader in AI-enabled drug discovery and development and ability to deliver better treatments to patients faster; expectations relating to early and late stage discovery, preclinical, and clinical programs, including timelines for commencement of and enrollment in studies, data readouts, presentations at scientific and medical meetings, and meetings with regulators; expectations and developments with respect to licenses and collaborations, including option exercises by partners and the amount and timing of potential milestone payments and royalties; prospective products and their potential future indications, differentiated profiles, and market opportunities; developments with Recursion OS, including the ability to discover and develop new medicines; and all other statements that are not historical facts. Forward-looking statements may or may not include identifying words such as “plan,” “will,” “may,” “could,” “should,” “expect,” “anticipate,” “intend,” “believe,” “estimate,” “project,” “designed to,” “potential,” “continue,” and similar terms. These statements are subject to known or unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements, including but not limited to: challenges inherent in pharmaceutical research and development, including the timing and results of preclinical and clinical programs, where the risk of failure is high and failure can occur at any stage prior to or after regulatory approval due to lack of sufficient efficacy, safety considerations, or other factors; the risk that interim, preliminary, or topline data from our clinical trials may change as more patient data become available and may not be predictive of final results; our ability to leverage and enhance our drug discovery platform; the performance and limitations of our artificial intelligence and machine learning models and the data on which they are trained; our reliance on third parties, including collaborators, contract research organizations, and manufacturers; our ability to initiate clinical trials and enroll patients on expected timelines; competition from other therapies and platforms; our ability to obtain financing for development activities and other corporate purposes; the success of our collaboration activities and our collaborators’ discretion over option exercises, program advancement, and funding; our ability to obtain regulatory approval of, and ultimately commercialize, drug candidates; our ability to obtain, maintain, and enforce intellectual property protections; cyberattacks or other disruptions to our technology systems; our ability to attract, motivate, and retain key employees and manage our growth; inflation and other macroeconomic issues; and other risks and uncertainties such as those described under the heading “Risk Factors” in our filings with the U.S. Securities and Exchange Commission, including our Annual Report on Form 10-K and our subsequent Quarterly Reports on Form 10-Q. All forward-looking statements speak only as of the date of this document and are based on management’s current estimates, projections, and assumptions, and Recursion undertakes no obligation to correct or update any such statements, whether as a result of new information, future developments, or otherwise, except to the extent required by applicable law.
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/e3f63cf6-70c6-464e-9e63-6608b58ef3fd
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How far does Recursion’s expected cash runway extend?
Recursion expects its cash runway to extend into 2029, including proceeds from the October 2026 follow-on offering. Cash operating expense guidance remains below $375 million for 2026, with guidance below $360 million for 2027.
What did Recursion’s REC-4881 trial show in FAP?
After 12 weeks of treatment, 87% of patients (13 of 15) had reduced total polyp burden, with a 47% median reduction. Twelve weeks after stopping treatment, 85% of evaluable patients (11 of 13) remained below baseline.
When does Recursion expect to start a REC-4881 registrational trial?
Recursion anticipates initiating a trial intended to support regulatory approval in the second half of 2027, pending ongoing FDA discussions. The company plans to provide additional details later in 2026.
What are Recursion’s next steps for REC-1245?
Recursion selected 45 mg once daily for exploratory expansion cohorts, including endometrial cancer. Preliminary endometrial cancer expansion data are expected in the second half of 2027. Dose escalation will also continue in other solid tumor indications.